Table 1 Demographic and clinical data of PD patients and HCs.

From: The longitudinal volumetric and shape changes of subcortical nuclei in Parkinson’s disease

 

PD Patients (n = 34, mean ± SD)

HCs (n = 32, mean ± SD)

pa,b

pc

pd

Baseline

Follow-up

Baseline

Follow-up

Age

59.43 ± 8.62

–

61.32 ± 7.16

–

0.336

–

–

Gender (F/M)

14/20

–

20/12

–

0.086

–

–

Education

7.68 ± 4.86

–

11.25 ± 3.37

–

0.010*

–

–

Duration

2.39 ± 1.90

4.52 ± 1.86

–

–

–

–

–

TIV

1484.21 ± 151.13

1478.38 ± 152.012

1428.44 ± 110.83

1414.07 ± 109.09

0.094

0.047*

 < 0.001**

LEDD

233.82 ± 256.28

457.49 ± 302.25

–

–

–

0.001**

–

H-Y stage

2.09 ± 0.66

2.16 ± 0.40

–

–

–

0.419

–

UPDRS total

27.18 ± 17.44

33.35 ± 18.02

–

–

–

0.049*

–

UPDRS part I

1.21 ± 1.43

1.50 ± 1.29

–

–

–

0.244

–

UPDRS part II

6.56 ± 4.67

8.88 ± 5.56

–

–

–

0.008**

–

UPDRS part III

18.68 ± 12.24

21.76 ± 12.46

–

–

–

0.170

–

UPDRS part IV

0.44 ± 0.75

1.21 ± 1.47

–

–

–

0.007**

–

MMSE

27.44 ± 3.56

26.71 ± 3.51

28.53 ± 1.39

28.13 ± 1.68

0.110

0.088

0.141

HAMD

4.85 ± 3.87

5.24 ± 5.10

2.72 ± 2.89

3.72 ± 5.08

0.014*

0.658

0.114

HAMA

4.79 ± 4.36

5.44 ± 4.85

4.28 ± 4.27

4.72 ± 5.54

0.631

0.516

0.569

PDQ-39

20.79 ± 19.56

24.29 ± 24.96

–

–

–

0.210

–

  1. LEDD daily levodopa equivalent dose, SD standard deviation.
  2. aUnpaired t-test between PD patients and HCs at baseline.
  3. bχ2 Likelihood Ratio in gender between PD patients and HCs at baseline.
  4. cPaired t-test between PD patients (baseline) and PD patients (follow-up).
  5. dPaired t-test between HCs (baseline) and HCs (follow-up).
  6. *p < 0.05. **p < 0.01. The P-values were FDR-adjusted.